10-Q: P3 Health Partners Reports Q1 2026 Financials

P3 Health Partners Inc. filed its Form 10-Q for the quarter ended March 31, 2026, reporting a net income of $3.04 million, a significant improvement from a net loss of $44.25 million in the prior year period.

Summary

• P3 Health Partners Inc. reported a net income of $3.04 million for the first quarter of 2026, a substantial turnaround from a net loss of $44.25 million in the same period of 2025.
• Total operating revenue increased by 4% to $386.39 million, driven by a 3% rise in capitated revenue to $379.50 million and a significant 86% increase in other revenue to $6.89 million.
• Medical expenses decreased by 10% to $336.02 million, attributed to a reduction in at-risk members and favorable reserve development.
• The company experienced a decrease in average at-risk members by 10% to 106,400, a result of intentional network and payer rationalization.
• Adjusted EBITDA showed a positive swing, moving from a loss of $22.19 million in Q1 2025 to a profit of $25.76 million in Q1 2026.
• The company continues to explore additional capital through debt and equity financing due to substantial doubt about its ability to continue as a going concern.
• Subsequent to the quarter, on April 27, 2026, the company entered into a Debt Exchange Agreement to exchange approximately $252.5 million of debt for preferred stock and a Securities Purchase Agreement to issue up to $70.0 million of units consisting of preferred stock and warrants.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report. While the financial turnaround is significant, the ongoing going concern issues and need for capital raise temper the positive outlook.

Positives

• Achieved net income of $3.04 million in Q1 2026, a significant improvement from a net loss of $44.25 million in Q1 2025.
• Total operating revenue increased by 4% to $386.39 million.
• Capitated revenue increased by 3% to $379.50 million, driven by strategic contractual restructuring and performance adjustments.
• Other revenue saw a substantial increase of 86% to $6.89 million.
• Medical expenses decreased by 10% to $336.02 million, indicating improved cost management.
• Adjusted EBITDA turned positive, reaching $25.76 million in Q1 2026 from a loss of $22.19 million in Q1 2025.
• Medical margin significantly improved to $73.66 million from $17.20 million in the prior year period.
• Gross profit improved to $50.37 million from $1.18 million in the prior year period.
• The company successfully raised $30 million in new financing through units consisting of preferred stock and warrants in April and May 2026.

Negatives

• The company has a working capital deficit of $353.3 million and a stockholders deficit of $143.5 million as of March 31, 2026.
• There is substantial doubt about the company's ability to continue as a going concern within one year after the issuance date of the financial statements.
• Average at-risk members decreased by 10% to 106,400.
• The company has a history of net losses and expects to continue incurring losses for the foreseeable future.
• The company relies on raising additional capital through debt and equity financing, with no assurance of availability on commercially acceptable terms.
• The company's long-term debt, net, increased to $259.57 million from $228.37 million.
• The company is subject to a civil investigative demand from the DOJ concerning arrangements with insurance agents and brokers.

Risks

• The company's ability to continue as a going concern due to its history of losses and need for additional capital.
• The risk of not being able to maintain compliance with debt covenants, which could lead to an event of default.
• The potential for future net losses and the possibility of never achieving or maintaining profitability.
• The company's limited operating history makes it difficult to evaluate future prospects and risks.
• The value of intangible assets may be reduced if they are determined to be impaired.
• Reliance on the management team and key employees; potential harm if qualified personnel cannot be retained.
• The success of growth strategies depends on identifying and developing new geographies, physician partners, payors, and patients.
• A decrease in the number of patients and physician partners or services provided could harm the business.
• Dependence on third-party payor reimbursement, particularly on a capitated basis, which could lead to delays or uncertainties.
• Termination or non-renewal of Medicare Advantage contracts or contracts with health plans could adversely affect revenue and operations.
• Dependence on affiliated professional entities and physician partners to manage care quality and costs.
• Reductions in health plan quality ratings could negatively impact the business.
• Developments affecting healthcare industry spending could adversely affect the business.
• Risk of IT system failures, security breaches, or cybersecurity deficiencies.
• Failure to comply with data protection, privacy, and security laws could adversely affect the business.
• Failure to adhere to complex government laws and regulations in the heavily regulated healthcare industry could result in fines or penalties.
• Arrangements with affiliated professional entities and physician partners could be found to constitute improper medical services or fee splitting.
• Inspections, reviews, audits, and investigations under government programs could have adverse findings.
• The impact of recent healthcare legislation and changes in healthcare spending is unknown but could be adverse.
• The company's sole significant asset is its minority economic interest in P3 LLC, which may not be sufficient to meet financial obligations.
• Changes in laws and regulations related to AI technologies could adversely affect products and services.
• Obligation to make significant payments under the Tax Receivable Agreement.
• Potential conflicts of interest with entities that are not limited in their ability to compete with the company.
• Failure to satisfy California regulations related to financial solvency and operational performance could lead to sanctions.
• Failure to meet Nasdaq continued listing requirements could result in delisting.
• Failure to maintain effective internal control over financial reporting could adversely affect the business and stock price.
• Potential failure to recognize anticipated benefits from acquisitions or dispositions, which could disrupt operations.
• The company is subject to a civil investigative demand from the DOJ concerning arrangements with insurance agents and brokers.

Future Outlook

The company expects to continue incurring losses for the foreseeable future and may never achieve or maintain profitability. Its capital requirements will depend on growth pace, medical cost management, member maturity, and its ability to raise capital. The company is exploring additional capital through debt and equity financing, but there is no assurance of availability on acceptable terms. Failure to secure funding could lead to curtailment of activities, discontinuation of operations, or asset sales.

Management Comments

• The company believes its platform, which realigns incentives and focuses on treating the full patient, is uniquely positioned to address healthcare challenges.
• The P3 Care Model differentiates itself through its patient-focused, physician-led, and broad delegated approach.
• The company's recurring revenue model from capitation offers predictable revenue and rewards high-quality care over high volume.
• Keeping members healthy is the primary objective, with a focus on delivering the right care in the right setting to impact outcomes.
• The company has demonstrated an ability to scale rapidly, expanding to a PCP network of approximately 2,300 physicians in 26 markets across five states.
• The company expects its PMPM revenue to continue improving as members participate longer in the care model and their health status is better understood.
• The company aims to generate operating efficiencies at both the market and enterprise level by leveraging its affiliate model and existing infrastructure.
• The company expects corporate, general and administrative expenses to increase in absolute dollars due to investments for growth and costs of operating as a public company.

Industry Context

StockSavvy.ai notes that P3 Health Partners operates within the highly competitive Medicare Advantage market, facing pressure from established health plans and evolving regulatory landscapes. The company's focus on a value-based care model, emphasizing physician partnerships and patient-centered care, aligns with broader industry trends shifting away from fee-for-service towards outcomes-based reimbursement.

Comparison to Industry Standards

• P3 Health Partners' medical expense as a percentage of total operating expense was 87% for Q1 2026, which is high compared to some integrated healthcare systems but may be typical for capitated models where the company bears direct risk for medical costs.
• The company's Adjusted EBITDA of $25.76 million in Q1 2026, compared to a loss of $22.19 million in Q1 2025, shows a significant positive swing, indicating improved operational efficiency and cost control, which is a key benchmark for success in the value-based care sector.
• The substantial increase in Medical Margin to $73.66 million from $17.20 million demonstrates a strong improvement in the core profitability of its capitated contracts, outperforming many industry peers who struggle with margin compression in similar models.
• The decrease in average at-risk members by 10% is a concern, as membership growth is a critical driver for success in this industry. Competitors often focus on aggressive member acquisition strategies.

Corporate Governance

Legal Proceedings

• The company received a civil investigative demand (CID) from the U.S. Department of Justice (DOJ) in June 2024 concerning arrangements with insurance agents and brokers, specifically related to marketing of broker programs and remuneration paid to Medicare Advantage brokers, agents, and agencies.

Related Party Transactions

• The company recorded Allymar service expenses of $3.0 million in Q1 2026, included in corporate, general and administrative expense.
• The company recorded Anderson service expenses of $0.1 million in Q1 2026, included in corporate, general and administrative expense.
• Transactions with Atrio Health Plans included $97.3 million in capitated revenue and $77.6 million in medical expense in Q1 2026.
• Interest expense related to claims in transit with Atrio Health Plans was $0.7 million in Q1 2026.
• The company issued warrants to purchase a total of 1.3 million shares of Class A common stock in connection with promissory notes to VGS.
• Subsequent to the quarter, the company exchanged approximately $252.5 million of debt owed to affiliates of Chicago Pacific Founders (CPF) for preferred stock.
• Subsequent to the quarter, the company entered into a Securities Purchase Agreement with affiliates of CPF to issue up to $70.0 million of units consisting of preferred stock and warrants.

Stakeholder Impact

• Shareholders: The positive financial turnaround and subsequent capital raise are positive, but the going concern warning and potential dilution from future equity issuances present risks.
• Creditors: The debt exchange agreement and new preferred stock issuance may impact the seniority and value of existing debt, though the exchange aims to reduce overall debt burden.
• Employees: Continued investment in growth and operations may lead to job security, but the going concern status could create uncertainty.
• Physician Partners: The company's focus on value-based care and physician-led models aims to benefit these partners through shared savings and improved patient care tools.
• Payors: The company's ability to manage costs and improve quality within capitated contracts is crucial for maintaining and growing relationships with health plans.

Next Steps

• Continue to explore raising additional capital through a combination of debt financing and equity issuances.
• Monitor compliance with debt covenants.
• Manage medical costs and improve member health outcomes.
• Execute on growth strategies by identifying and developing new geographies, physician partners, payors, and patients.
• Integrate new financing and debt exchange arrangements to strengthen financial position.

Key Dates

Recommendation

The company has demonstrated a significant operational and financial turnaround, moving from a substantial net loss to profitability and positive Adjusted EBITDA. However, the persistent going concern warning, substantial deficits, and ongoing need for capital raises introduce significant risk. The recent debt exchange and preferred stock issuance provide some immediate relief but also introduce new capital structures and potential dilution. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the company's ability to achieve sustainable profitability and resolve its going concern issues.

Keywords

P3 Health Partners, Form 10-Q, Quarterly Report, Medicare Advantage, Population Health Management, Capitated Revenue, Medical Expense, Adjusted EBITDA, Going Concern, Debt Exchange, Preferred Stock, Warrants, Healthcare, Financial Statements